Comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175.

Genuth (1) discusses in a Counterpoint article several arguments against the use of sulfonylureas (SUs) as an add-on therapy to metformin. We understand that in this format he makes arguments against the use of SUs; however, we could not appreciate his oversimplification by ignoring within-class differences. Specifically, the safety of gliclazide is not recognized. In the 2013 Dutch type 2 diabetes guidelines from the …